Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Article

Open Access Gateway

Economic Evaluation of Intensive Inpatient Treatments for Severely Obese Children and Adolescents

Makkes S.a · van Dongen J.M.a · Renders C.M.a · van der Baan-Slootweg O.H.b · Seidell J.C.a · Bosmans J.E.a

Author affiliations

aDepartment of Health Sciences and the EMGO Institute for Health and Care Research, VU University Amsterdam, Amsterdam, The Netherlands; bMerem Childhood Obesity Center, Heideheuvel, Hilversum, The Netherlands

Corresponding Author

Prof. Dr. Jacob C Seidell

Department of Health Sciences, Faculty of Earth and Life Sciences

VU University Amsterdam

De Boelelaan 1085, 1081 HV Amsterdam, the Netherlands

j.c.seidell@vu.nl

Related Articles for ""

Obes Facts 2017;10:458-472

Do you have an account?

Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



Abstract

Background: Considering the large economic consequences of severe childhood obesity for the society, we aimed to conduct an economic evaluation comparing two intensive 1-year lifestyle treatments with varying inpatient periods for severely obese children and adolescents with regard to standard deviation score BMI (SDS-BMI) and quality-adjusted life years (QALYs). Methods: An economic evaluation from a societal perspective accompanying a randomized controlled trial with a 24-month follow-up. 80 participants (8-19 years) with severe obesity were included. Participants received an intensive 1-year lifestyle treatment with an inpatient period of 2 months (short-stay group) or 6 months (long-stay group). Data were collected at baseline, 6, 12 ,and 24 months and included SDS-BMI and QALYs. Results: SDS-BMI decreased in the first 6 months of treatment, stabilized in the second 6 months, and increased during the 2nd year in both groups. After 24 months, SDS-BMI was similar in both groups, but remained lower than baseline values (mean difference -0.24, 95% CI -0.42; -0.06). There was no difference in QALYs between the groups after 24 months. For SDS-BMI, the probability of the short-stay treatment being cost-effective in comparison with the long-stay treatment was 1 at a willingness-to-pay of 0 EUR/unit of effect, which slowly decreased to 0.54 for larger willingness-to-pay values. Conclusions: Based on the results of this study, the short-stay treatment is considered to be more cost-effective from the societal perspective in comparison with the long-stay treatment. Future research should provide insight in whether the short-stay treatment is cost-effective in comparison with usual care.

© 2017 The Author(s) Published by S. Karger GmbH, Freiburg


References

  1. Jackson-Leach R, Lobstein T: Estimated burden of paediatric obesity and co-morbidities in Europe. Part 1. The increase in the prevalence of child obesity in Europe is itself increasing. Int J Pediatr Obes 2006;1:26-32.
  2. Ogden CL, Carroll MD, Kit BK, Flegal KM: Prevalence of obesity in the United States, 2009-2010. NCHS Data Brief 2012;82:1-8.
    External Resources
  3. Schönbeck Y, Talma H, van Dommelen P, Bakker B, Buitendijk SE, HiraSing RA, van Buuren S: Increase in prevalence of overweight in Dutch children and adolescents: a comparison of nationwide growth studies in 1980, 1997 and 2009. PloS One 2011;6:e27608.
  4. Skelton JA, Cook SR, Auinger P, Klein JD, Barlow SE: Prevalence and trends of severe obesity among us children and adolescents. Acad Pediatr 2009;9:322-329.
  5. Yang L, Colditz GA: Prevalence of overweight and obesity in the United States, 2007-2012. JAMA Intern Med 2015;175:1412-1413.
  6. Statistics Netherlands: Lengte en gewicht van personen, ondergewicht en overgewicht; vanaf 1981, 2016. http://statline.cbs.nl/StatWeb/publication/?DM=SLNL&PA=81565NED (last accessed September 27, 2017).
  7. Dietz WH: Health consequences of obesity in youth: childhood predictors of adult disease. Pediatrics 1998;101:518-525.
    External Resources
  8. Franks PW, Hanson RL, Knowler WC, Sievers ML, Bennett PH, Looker HC: Childhood obesity, other cardiovascular risk factors, and premature death. N Engl J Med 2010;362:485-493.
  9. Ludwig DS: Childhood obesity - the shape of things to come. N Engl J Med 2007;357:2325-2327.
  10. Berenson GS: Health consequences of obesity. Pediatr Blood Cancer 2012;58:117-121.
  11. Makkes S, Renders CM, Bosmans JE, van der Baan-Slootweg OH, Seidell JC: Cardiometabolic risk factors and quality of life in severely obese children and adolescents in the Netherlands. BMC Pediatr 2013;13:1.
  12. Falkner NH, Neumark‐Sztainer D, Story M, Jeffery RW, Beuhring T, Resnick MD: Social, educational, and psychological correlates of weight status in adolescents. Obes Res 2001;9:32-42.
  13. Puder J, Munsch S: Psychological correlates of childhood obesity. Int J Obes 2010;34:S37-S43.
  14. Van Wijnen LG, Boluijt PR, Hoeven-Mulder HB, Bemelmans WJ, Wendel-Vos GW: Weight status, psychological health, suicidal thoughts, and suicide attempts in Dutch adolescents: RESULTS from the 2003 e-movo project. Obesity (Silver Spring) 2010;18:1059.
  15. Schwimmer JB, Burwinkle TM, Varni JW: Health-related quality of life of severely obese children and adolescents. JAMA 2003;289:1813-1819.
  16. Zeller MH, Roehrig HR, Modi AC, Daniels SR, Inge TH: Health-related quality of life and depressive symptoms in adolescents with extreme obesity presenting for bariatric surgery. Pediatrics 2006;117:1155-1161.
  17. Trasande L, Chatterjee S: The impact of obesity on health service utilization and costs in childhood. Obesity (Silver Spring) 2009;17:1749-1754.
  18. Withrow D, Alter D: The economic burden of obesity worldwide: a systematic review of the direct costs of obesity. Obes Rev 2011;12:131-141.
  19. Trasande L, Elbel B: The economic burden placed on healthcare systems by childhood obesity. Expert Rev Pharmacoecon Outcomes Res 2012;12:39-45.
  20. Batscheider A, Rzehak P, Teuner CM, Wolfenstetter SB, Leidl R, von Berg A, Berdel D, Hoffmann B, Heinrich J: Development of BMI values of German children and their healthcare costs. Econ Hum Biol 2014;12:56-66.
  21. Singh AS, Mulder C, Twisk JW, Van Mechelen W, Chinapaw MJ: Tracking of childhood overweight into adulthood: a systematic review of the literature. Obes Rev 2008;9:474-488.
  22. Freedman DS, Mei Z, Srinivasan SR, Berenson GS, Dietz WH: Cardiovascular risk factors and excess adiposity among overweight children and adolescents: THE Bogalusa Heart Study. J Pediatr 2007;150:12-17. e12.
  23. Baker JL, Olsen LW, Sørensen TI: Childhood body-mass index and the risk of coronary heart disease in adulthood. N Engl J Med 2007;357:2329-2337.
  24. Sonntag D, Ali S, Lehnert T, Konnopka A, Riedel‐Heller S, König HH: Estimating the lifetime cost of childhood obesity in Germany: results of a Markov model. Pediatr Obes 2015;10:416-422.
  25. Trasande L: How much should we invest in preventing childhood obesity? Health Affairs 2010;29:372-378.
  26. Krebs NF, Himes JH, Jacobson D, Nicklas TA, Guilday P, Styne D: Assessment of child and adolescent overweight and obesity. Pediatrics 2007;120(suppl 4):S193-S228.
  27. Seidell J, Halberstadt J, Noordam H, Niemer S: An integrated health care standard for the management and prevention of obesity in the Netherlands. Fam Pract 2012;29:i153-i156.
  28. Makkes S, Halberstadt J, Renders CM, Bosmans JE, van der Baan-Slootweg OH, Seidell JC: Cost-effectiveness of intensive inpatient treatments for severely obese children and adolescents in the Netherlands; a randomized controlled trial (HELIOS). BMC Public Health 2011;11:1.
  29. Oude Luttikhuis H, Baur L, Jansen H, Shrewsbury VA, O'Malley C, Stolk RP, Summerbell CD: Interventions for treating obesity in children. Cochrane Database Syst Rev 2009;1:CD001872.
  30. Kelly AS, Barlow SE, Rao G, Inge TH, Hayman LL, Steinberger J, Urbina EM, Ewing LJ, Daniels SR: Severe obesity in children and adolescents: identification, associated health risks, and treatment approaches a scientific statement from the American Heart Association. Circulation 2013;128:1689-1712.
  31. Hirasing R, Fredriks A, Van Buuren S, Verloove-Vanhorick S, Wit J: Increased prevalence of overweight and obesity in Dutch children, and the detection of overweight and obesity using international criteria and new reference diagrams (in Dutch). Nederlands Tijdschrift voor Geneeskunde 2001;145:1303-1308.
    External Resources
  32. Pocock SJ: Clinical Trials: A Practical Approach. New York, Wiley & Sons, 2013.
  33. Cole TJ, Bellizzi MC, Flegal KM, Dietz WH: Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ 2000;320:1240.
    External Resources
  34. Stichting Kind en Groei: Growth analyzer, 2010. http://kindengroei.nl/stichting-kind-en-groei/kindergroeimeter/ (last accessed September 27, 2017).
  35. EuroQol Group: EuroQol - a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208.
  36. Lamers L, Stalmeier P, McDonnell J, Krabbe P, van Busschbach J: Measuring the quality of life in economic evaluations: the Dutch eq-5d tariff (in Dutch). Nederlands Tijdschrift voor Geneeskunde 2005;149:1574-1578.
    External Resources
  37. Hakkaart-van Roijen L, Tan S, Bouwmans C: Methods and standard cost prices for economic evaluations in healthcare (in Dutch). Version 2010, Diemen, College van Zorgverzekeringen, 2011.
  38. Brouwer WB, Van Exel N, Baltussen RM, Rutten FF: A dollar is a dollar is a dollar - or is it? Value Health 2006;9:341-347.
  39. van Dongen JM, van Wier MF, Tompa E, Bongers PM, van der Beek AJ, van Tulder MW, Bosmans JE: Trial-based economic evaluations in occupational health: principles, methods, and recommendations. J Occup Environl Med 2014;56:563.
  40. Statistics Netherlands: Consumenten prijs index. 2011. http://nl.inflation.eu/inflatiecijfers/nederland/historische-inflatie/cpi-inflatie-nederland.aspx (last accessed September 27, 2017).
  41. van der Baan-Slootweg O, Benninga MA, Beelen A, van der Palen J, Tamminga-Smeulders C, Tijssen JG, van Aalderen WM: Inpatient treatment of children and adolescents with severe obesity in the Netherlands: a randomized clinical trial. JAMA Pediatr 2014;168:807-814.
  42. White IR, Royston P, Wood AM: Multiple imputation using chained equations: issues and guidance for practice. Stat Med 2011;30:377-399.
  43. Willan AR, Briggs AH, Hoch JS: Regression methods for covariate adjustment and subgroup analysis for non‐censored cost‐effectiveness data. Health Econ 2004;13:461-475.
  44. Black WC: The CE plane a graphic representation of cost-effectiveness. Med Decis Making 1990;10:212-214.
  45. Fenwick E, O'Brien BJ, Briggs A: Cost‐effectiveness acceptability curves - facts, fallacies and frequently asked questions. Health Econ 2004;13:405-415.
  46. Levine MD, Ringham RM, Kalarchian MA, Wisniewski L, Marcus MD: Is family‐based behavioral weight control appropriate for severe pediatric obesity? Int J Eat Disord 2001;30:318-328.
  47. Johnston CA, Tyler C, Palcic JL, Stansberry SA, Gallagher MR, Foreyt JP: Smaller weight changes in standardized body mass index in response to treatment as weight classification increases. J Pediatr 2011;158:624-627.
  48. Savoye M, Shaw M, Dziura J, Tamborlane WV, Rose P, Guandalini C, Goldberg-Gell R, Burgert TS, Cali AM, Weiss R: Effects of a weight management program on body composition and metabolic parameters in overweight children: a randomized controlled trial. JAMA 2007;297:2697-2704.
  49. Danielsson P, Kowalski J, Ekblom Ö, Marcus C: Response of severely obese children and adolescents to behavioral treatment. Arch Pediatr Adolesc Medic 2012;166:1103-1108.
  50. Kalarchian MA, Levine MD, Arslanian SA, Ewing LJ, Houck PR, Cheng Y, Ringham RM, Sheets CA, Marcus MD: Family-based treatment of severe pediatric obesity: randomized, controlled trial. Pediatrics 2009;124:1060-1068.
  51. Knöpfli BH, Radtke T, Lehmann M, Schätzle B, Eisenblätter J, Gachnang A, Wiederkehr P, Hammer J, Brooks-Wildhaber J: Effects of a multidisciplinary inpatient intervention on body composition, aerobic fitness, and quality of life in severely obese girls and boys. J Adolesc Health 2008;42:119-127.
  52. Rolland-Cachera M, Thibault H, Souberbielle J, Soulie D, Carbonel P, Deheeger M, Roinsol D, Longueville E, Bellisle F, Serog P: Massive obesity in adolescents: dietary interventions and behaviours associated with weight regain at 2 y follow-up. Int J Obes 2004;28:514-519.
  53. Petrou S, Gray A: Economic evaluation alongside randomised controlled trials: design, conduct, analysis, and reporting. BMJ 2011;342:d1548.

Article / Publication Details

First-Page Preview
Abstract of Original Article

Received: July 27, 2016
Accepted: January 25, 2017
Published online: October 07, 2017
Issue release date: October 2017

Number of Print Pages: 15
Number of Figures: 4
Number of Tables: 5

ISSN: 1662-4025 (Print)
eISSN: 1662-4033 (Online)

For additional information: https://www.karger.com/OFA


Open Access License / Drug Dosage / Disclaimer

This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND). Usage and distribution for commercial purposes as well as any distribution of modified material requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.